Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Andlauer Healthcare Group Inc T.AND

Alternate Symbol(s):  ANDHF

Andlauer Healthcare Group Inc. is a Canada-based supply chain management company. The Company offers a robust platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector. Its 3PL services include customized logistics, distribution and packaging solutions for healthcare manufacturers across Canada. Its specialized transportation services in Canada, including air freight forwarding, ground transportation, dedicated delivery and last-mile services, provide a one-stop shop for clients' healthcare transportation needs. It operates in two segments: Specialized Transportation and Healthcare Logistics. Through its complementary service offerings, available across a coast-to-coast distribution network, it strives to accommodate the full range of its clients' specialized supply chain needs. The Company also provides specialized ground transportation services, primarily to the healthcare sector, across the 48 contiguous U.S. states.


TSX:AND - Post by User

Post by retiredcfon Nov 19, 2021 9:33am
118 Views
Post# 34144983

TD Upgrade

TD Upgrade

Andlauer Healthcare Group Inc.

(AND-T) C$47.47

Q3/21; Growing Equity Value Not Reflected in Share Price Event

After market close on November 11, Andlauer Healthcare Group (AHG) reported Q3/21 results. EBITDA of $28.0 million was in line with our forecast of $28.3 million and consensus of $28.7 million. EPS of $0.31 was up 41% y/y, in line with our forecast of $0.31 and consensus of $0.33. We note that there was one outlier, excluding which, consensus was $0.31.

Impact: SLIGHTLY POSITIVE

We are upgrading Andlauer Healthcare to BUY from Hold and increasing our target price to $55.00 from $54.00. The increase to our target price is due to the impact of shifting forward our valuation period by one quarter. Due to recent share- price weakness, a steady increase in our target price since early-2021, and the resulting 12-month expected return, we believe that investors should acquire the shares. Management has been delivering strong and predictable growth, along with acquisitions, which, we believe, will provide investors with exposure to specialized segments of the U.S. market, and greater long-term upside. Financial leverage has remained conservative while recently deploying capital into what we view as winning acquisitions.

The acquisitions of Boyle and Skelton USA are being completed at a combined valuation of approximately 7.1x trailing EBITDA, an attractive valuation when compared with AHG's current 2022 valuation of 15.3x EBITDA, and our target valuation multiple of 16.0x. Our target EBITDA multiple represents a premium to the company's comparable group average (Exhibit 2), but is well below the only comparable that also boasts greater than 20% EBITDA margins and an ROIC above 20%. To the extent that the pandemic has been contributing to AHG's premium valuation multiples since its IPO, we believe that there could eventually be downside risk to its multiple, though we believe that prolonged recovery, its growth opportunities, and capital efficiency will limit this risk over the next 12 months.

TD Investment Conclusion

We believe that AHG deserves a premium valuation relative to a group of comparable companies due to its above-average historical and forecast growth, prudent financial leverage, and track-record of strong margins and returns on capital, along with its competitive position within an industry that offers good economic resiliency.


<< Previous
Bullboard Posts
Next >>